Merck & Co Inc
Pharmaceuticals
Merck & Co Inc (MRK) Stock News
The latest MRK headlines and market coverage — 2 recent stories, updated throughout the day.
- Zacks Investment Research·Neutral
Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?
The article compares brokerage analyst recommendations (ABR) with Zacks Rank as investment decision tools. While Merck has a favorable average brokerage recommendation of 1.67 (Buy-equivalent), the article cautions that brokerage firms often exhibit positive bias due to vested interests. Zacks Rank, based on earnings estimate revisions rather than analyst opinions, is presented as a more reliable predictor of near-term stock price movements. Merck received a Zacks Rank #3 (Hold) due to unchanged earnings estimates, suggesting caution despite the bullish brokerage consensus.
- Zacks Investment Research·Neutral
AZN vs. MRK: Comparing Keytruda, Pipelines and Growth Strategies
AstraZeneca and Merck are compared as investment opportunities in the pharmaceutical sector. AstraZeneca targets $80 billion in revenues by 2030 with 20 planned new medicine launches but faces patent expirations, pricing pressures in China, and recent pipeline setbacks. Merck relies heavily on blockbuster drug Keytruda (peak sales $35 billion by 2028) but faces patent expiration in 2028 and biosimilar competition. Merck receives a Zacks Rank #3 (Hold) while AstraZeneca receives Zacks Rank #5 (Strong Sell), making Merck the preferred choice despite higher valuation multiples.